1603 related articles for article (PubMed ID: 29444952)
41. Activity of ceftazidime-avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance.
López-Hernández I; Alonso N; Fernández-Martínez M; Zamorano L; Rivera A; Oliver A; Conejo MC; Martínez-Martínez L; Navarro F; Pascual A
Enferm Infecc Microbiol Clin; 2017 Oct; 35(8):499-504. PubMed ID: 27887765
[TBL] [Abstract][Full Text] [Related]
42. Management of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: current evidence and future prospects.
Sheu CC; Lin SY; Chang YT; Lee CY; Chen YH; Hsueh PR
Expert Rev Anti Infect Ther; 2018 Mar; 16(3):205-218. PubMed ID: 29402125
[TBL] [Abstract][Full Text] [Related]
43. Extended-spectrum beta-lactamases. An overview.
Patterson JE
Postgrad Med; 2001 Feb; 109(2 Suppl):32-8. PubMed ID: 19667555
[TBL] [Abstract][Full Text] [Related]
44. Optimizing therapy in carbapenem-resistant Enterobacteriaceae infections.
Tumbarello M; Losito AR; Giamarellou H
Curr Opin Infect Dis; 2018 Dec; 31(6):566-577. PubMed ID: 30379732
[TBL] [Abstract][Full Text] [Related]
45. Diversity of resistance mechanisms in carbapenem-resistant Enterobacteriaceae at a health care system in Northern California, from 2013 to 2016.
Senchyna F; Gaur RL; Sandlund J; Truong C; Tremintin G; Kültz D; Gomez CA; Tamburini FB; Andermann T; Bhatt A; Tickler I; Watz N; Budvytiene I; Shi G; Tenover FC; Banaei N
Diagn Microbiol Infect Dis; 2019 Mar; 93(3):250-257. PubMed ID: 30482638
[TBL] [Abstract][Full Text] [Related]
46. Prevalence and Molecular Characteristics of Carbapenemase-Producing Enterobacteriaceae From Five Hospitals in Korea.
Jeong SH; Kim HS; Kim JS; Shin DH; Kim HS; Park MJ; Shin S; Hong JS; Lee SS; Song W
Ann Lab Med; 2016 Nov; 36(6):529-35. PubMed ID: 27578505
[TBL] [Abstract][Full Text] [Related]
47. Phenotypic Identification, Frequency Distribution and Antibiogram of Carbapenemase Producing Enterobacteriaceae in Clinical Isolates.
Ansari M; Munir T; Saad N
J Coll Physicians Surg Pak; 2018 Apr; 28(4):274-278. PubMed ID: 29615166
[TBL] [Abstract][Full Text] [Related]
48. Prevalence and antibiotic susceptibility pattern of CTX-M type extended-spectrum β-lactamases among clinical isolates of gram-negative bacilli in Jimma, Ethiopia.
Zeynudin A; Pritsch M; Schubert S; Messerer M; Liegl G; Hoelscher M; Belachew T; Wieser A
BMC Infect Dis; 2018 Oct; 18(1):524. PubMed ID: 30342476
[TBL] [Abstract][Full Text] [Related]
49. Correlation of β-Lactamase Production and Colistin Resistance among Enterobacteriaceae Isolates from a Global Surveillance Program.
Bradford PA; Kazmierczak KM; Biedenbach DJ; Wise MG; Hackel M; Sahm DF
Antimicrob Agents Chemother; 2015 Dec; 60(3):1385-92. PubMed ID: 26666920
[TBL] [Abstract][Full Text] [Related]
50. Mono vs. combo regimens with novel beta-lactam/beta-lactamase inhibitor combinations for the treatment of infections due to carbapenemase-producing Enterobacterales: insights from the literature.
Meini S; Viaggi B; Tascini C
Infection; 2021 Jun; 49(3):411-421. PubMed ID: 33534065
[TBL] [Abstract][Full Text] [Related]
51. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.
Lomovskaya O; Sun D; Rubio-Aparicio D; Nelson K; Tsivkovski R; Griffith DC; Dudley MN
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848018
[TBL] [Abstract][Full Text] [Related]
52. Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae.
Sousa A; Pérez-Rodríguez MT; Soto A; Rodríguez L; Pérez-Landeiro A; Martínez-Lamas L; Nodar A; Crespo M
J Antimicrob Chemother; 2018 Nov; 73(11):3170-3175. PubMed ID: 30099490
[TBL] [Abstract][Full Text] [Related]
53. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?
Perez F; El Chakhtoura NG; Papp-Wallace KM; Wilson BM; Bonomo RA
Expert Opin Pharmacother; 2016; 17(6):761-81. PubMed ID: 26799840
[TBL] [Abstract][Full Text] [Related]
54. Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope.
Avery LM; Nicolau DP
Int J Antimicrob Agents; 2018 Nov; 52(5):688-691. PubMed ID: 30044946
[TBL] [Abstract][Full Text] [Related]
55. Treatment of infections caused by carbapenemase-producing Enterobacteriaceae.
Rodríguez-Baño J; Cisneros JM; Gudiol C; Martínez JA
Enferm Infecc Microbiol Clin; 2014 Dec; 32 Suppl 4():49-55. PubMed ID: 25542052
[TBL] [Abstract][Full Text] [Related]
56. Carbapenem non-susceptible enterobacteriaceae in Quebec, Canada: results of a laboratory surveillance program (2010-2012).
Lefebvre B; Lévesque S; Bourgault AM; Mulvey MR; Mataseje L; Boyd D; Doualla-Bell F; Tremblay C
PLoS One; 2015; 10(4):e0125076. PubMed ID: 25910041
[TBL] [Abstract][Full Text] [Related]
57. Emerging Carbapenem-Resistant
Tilahun M; Kassa Y; Gedefie A; Ashagire M
Infect Drug Resist; 2021; 14():4363-4374. PubMed ID: 34707380
[TBL] [Abstract][Full Text] [Related]
58. Direct β-Lactam Inactivation Method: a New Low-Cost Assay for Rapid Detection of Carbapenemase- or Extended-Spectrum-β-Lactamase-Producing
Bianco G; Boattini M; Iannaccone M; Fossati L; Cavallo R; Costa C
J Clin Microbiol; 2019 Dec; 58(1):. PubMed ID: 31694972
[TBL] [Abstract][Full Text] [Related]
59. Carbapenems and alternative β-lactams for the treatment of infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: What impact on intestinal colonisation resistance?
Woerther PL; Lepeule R; Burdet C; Decousser JW; Ruppé É; Barbier F
Int J Antimicrob Agents; 2018 Dec; 52(6):762-770. PubMed ID: 30176355
[TBL] [Abstract][Full Text] [Related]
60. Extended-spectrum beta-lactamase-producing organisms.
Falagas ME; Karageorgopoulos DE
J Hosp Infect; 2009 Dec; 73(4):345-54. PubMed ID: 19596491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
